Allen Institute’s cell lines could lead to new drugs for hypertrophic cardiomyopathy
The Allen Institute, a Seattle-based research institute, has introduced new stem cell lines that could help scientists identify personalized treatment approaches for Hypertrophic cardiomyopathy (HCM), a potentially lethal heart disease. HCM is particularly challenging to study because there are 1,500 mutations in 25 different genes that can cause the disease.
To address this challenge, the Allen Institute created its first “disease-specific” cell line, which helps scientists study cells with only specific mutations, furthering the potential to develop more tailored treatments.
The new cell line collection is a result of a partnership between the University of Washington, the University of California, and Standford.